The pharmaceutical company Moderna presented its new bivalent vaccine against Covid-19 on Tuesday, which is more effective against the subvariants of Omicron.
The effectiveness of this new vaccine depends on the circulating strain, the closer the circulating strain is to the variant targeted by the vaccine, the more effective the vaccine will be.
Karine Lacombe, head of the infectious diseases department at St-Antoine (AP-HP)
This vaccine, like that of Pfizer, has been “adapted” to the viruses currently in circulation, thanks to the very promising technology of messenger RNA. They will be used first for reminders of fragile people.
And after Covid? Messenger RNA raises immense hopes in the face of pathologies other than Covid-19, and not just viral ones.
If its applications are recent, the technology in question is anything but new: it has even earned…